Inflammatory arthritis: A newly recognized adverse event of immune checkpoint blockade

Oncologist

Volumn 22, Issue 6, 2017, Pages 627-630

  Naidoo, Jarushka ^a   Cappelli, Laura C ^b   Forde, Patrick M ^a   Marrone, Kristen A ^a   Lipson, Evan J ^a   Hammers, Hans J ^a   Sharfman, William H ^a   Le, Dung T ^a   Baer, Alan N ^b   Shah, Ami A ^b   Albayda, Jemima ^b   Manno, Rebecca L ^b   Haque, Uzma ^b   Gutierrez, Anna Kristina ^b   Bingham, Clifton O ^b   Brahmer, Julie R ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; IPILIMUMAB; LEFLUNOMIDE; METHOTREXATE; NAPROXEN; NIVOLUMAB; PREDNISONE; SALAZOSULFAPYRIDINE; TOCILIZUMAB; TOFACITINIB; TUMOR NECROSIS FACTOR; PROGRAMMED DEATH 1 RECEPTOR;

ARTHRALGIA; CLINICAL TRIAL (TOPIC); HUMAN; METASTATIC MELANOMA; NOTE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SMALL CELL LUNG CANCER; SPONDYLARTHRITIS; SYNOVIAL FLUID; TENOSYNOVITIS; ARTHRITIS; IMMUNOLOGY; INFLAMMATION; PATHOLOGY;

ARTHRITIS; HUMANS; INFLAMMATION; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 85020884329     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2016-0390     Document Type: Note

References (42)

1. Weber JS, D’Angelo SP, Minor D et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015;16:375-384.
2. Larkin J, Chiarion-Sileni V, Gonzalez R et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015;373:23-34.
3. Brahmer J, Reckamp KL, Baas P et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015;373:123-135.
4. Borghaei H, Paz-Ares L, Horn L et al. Nivolumab versus docetaxel in advanced nonsquamous nonsmall-cell lung cancer. N Engl J Med 2015;373:1627-1639.
5. Herbst RS, Baas P, Kim DWet al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. Lancet 2016;387:1540-1550.
6. Fehrenbacher L, Spira A, BallingerMet al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): A multicentre, open-label, phase 2 randomised controlled trial. Lancet 2016;9:1540-1550.
7. Motzer RJ, Escudier B,McDermottDF et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015;373:1803-1813.
8. Ansell SM, Lesokhin AM, Borrello I et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med 2015;372:311-319.
9. Rosenberg JE, Hoffman-Censits J, Powles T et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial. Lancet 2016;387:1909-1920.
10. Ferris RL, Blumenschein G, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 2016;375:1856-1867.
11. Robert C, Schachter J, Long GV et al. Pembrolizumab versus ipilimumab in advancedmelanoma. N Engl JMed 2015;372:2521-2532.
12. Ferris RL, Blumenschein G, Jr., Fayette J et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 2016;375:1856-1867.
13. Seiwert TY, Burtness B, Mehra R et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): An open-label, multicentre, phase 1b trial. Lancet Oncol 2016;17:956-965.
14. Naidoo J, Page DB, Li BT et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 2015;26:2375-2391.
15. Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012;30:2691-2697.
16. Beck KE, Blansfield JA, Tran KQ et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006;24:2283-2289.
17. Abdel-Rahman O, ElHalawani H, Fouad M. Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a metaanalysis. Future Oncol 2016;12:413-425.
18. Min L, Hodi FS, Giobbie-Hurder A et al. Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis:A retrospective cohort study. Clin Cancer Res 2015;21:749-755.
19. Iwama S, De Remigis A, Callahan MK et al. Pituitary expression of CTLA-4mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med 2014;6:230ra245.
20. Naidoo J, Schindler K, Querfeld C et al. Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1. Cancer Immunol Res 2016;4:383-389.
21. Minkis K, Garden BC,Wu S et al. The risk of rash associated with ipilimumab in patients with cancer:A systematic review of the literature and meta-analysis. J Am Acad Dermatol 2013;69:e121-e128.
22. Naidoo J,Wang X,Woo KM et al. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. J Clin Oncol 2017;35:709-717.
23. Bashey A, Medina B, Corringham S et al. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood 2009;113:1581-1588.
24. Hodi FS, Lee S, McDermott DF et al. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastaticmelanoma: A randomized clinical trial. JAMA 2014;312:1744-1753.
25. Chan MM, Kefford RF, Carlino M et al. Arthritis and tenosynovitis associated with the anti-PD1 antibody pembrolizumab in metastatic melanoma. J Immunother 2015;38:37-39.
26. de Velasco G BB, Choueiri TK. Autoimmune arthropathy and uveitis as complications of programmed death 1 inhibitor treatment. Arthritis Rheumatol 2016;68:556-557.
27. Law-Ping-Man S, Martin A, Briens E et al. Psoriasis and psoriatic arthritis induced by nivolumab in a patient with advanced lung cancer. Rheumatology (Oxford) 2016;55:2087-2089.
28. Cappelli LC, Gutierrez AK, Baer AN et al. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis 2016; 76:43-50.
29. Opdivo (nivolumab): Immune-Mediated Adverse Reactions Management Guide. Available at http://www.opdivohcp.bmscustomerconnect.com/servlet/servlet.FileDownload?file500Pi000000Hj19REAR. AccessedMarch 31, 2017.
30. Merck. Keytruda (pembrolizumab) prescribing information. 2015. Available at https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf. Accessed April 13, 2017.
31. Common Terminology Criteria for Adverse Events (CTCAE): Version 4.0. Available at http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf. Accessed March 31, 2017.
32. Woodworth T, Furst DE, Alten R et al. Standardizing assessment and reporting of adverse effects in rheumatology clinical trials II: The Rheumatology Common Toxicity Criteria v.2.0. J Rheumatol 2007; 34:1401-1414.
33. Cappelli LC, Gutierrez AK, Baer AN et al. Rheumatologic Consequences of Immunotherapy to Treat Malignancies: The Tip of an Iceberg. In American College of Rheumatology AVR/ARHP Annual Meeting 2016.Washington, DC:, 2016.
34. Detert J, Bastian H, Listing J et al. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis:HIT HARD, an investigator-initiated study. Ann Rheum Dis 2013;72:844-850.
35. Breedveld FC, Weisman MH, Kavanaugh AF et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37.
36. St Clair EW, van der Heijde DM, Smolen JS et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial. Arthritis Rheum 2004;50:3432-3443.
37. Maini R, St Clair EW, Breedveld F et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate:A randomised phase III trial. ATTRACT Study Group. Lancet 1999;354:1932-1939.
38. Tanaka T, Ogata A, Narazaki M. Tocilizumab for the treatment of rheumatoid arthritis. Expert Rev Clin Immunol 2010;6:843-854.
39. Xie F, Yun H, Bernatsky S et al. Risk for gastrointestinal perforation among rheumatoid arthritis patients receiving tofacitinib, tocilizumab, or other biologics. Arthritis Rheumatol 2016;68:2612-2617.
40. Ruderman EM, Pope RM. Drug insight: Abatacept for the treatment of rheumatoid arthritis. Nat Clin Pract Rheumatol 2006;2:654-660.
41. Aletaha D, Neogi T, Silman AJ et al. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62:2569-2581.
42. Rudwaleit M, Landewe R, van der Heijde D et al. The development of Assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part I): Classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis 2009;68:770-776.